EASL 2013: Daclatasvir plus Interferon Cures More Genotype 2/3 Hepatitis C Patients
Adding the HCV NS5A inhibitor daclatasvir to pegylated interferon and ribavirin for 12 or 16 weeks led to higher response rates for previously untreated people with genotype 2 or 3 hepatitis C, according to results from the COMMAND study reported last week at the EASL International Liver Congress in Amsterdam.
Join the discussion below, or Read more at HIV and Hepatitis.
#1 May 4, 2013
This disease is now cured in most people with this treatment, what a great job by the medical researchers
Add your comments below
|Morgellons - What I believe it really is (Oct '12)||8 hr||real||372|
|Poll: 70 percent of Kentuckians support $1 toba...||12 hr||Say What||40|
|Pregnancy Symptoms - 12 Very Early Symptoms of ... (Jun '07)||14 hr||Yougogirl||7,319|
|Major shift as Trump opens way for Medicaid wor...||16 hr||spocko||113|
|Esophagus Spasm - How my mom STOPS her Esophage... (May '12)||Tue||Beth||297|
|Millions more Americans were uninsured in 2017||Tue||notfromhere||1|
|Ohio approves state smoking ban (Nov '06)||Tue||TruthBeTold||76,023|
|watching wife get pregnant by another man (Jan '17)||Jan 14||willthis23||35|
Find what you want!
Search Health Forum Now
Copyright © 2018 Topix LLC